Zionexa completes a second $5 Million capital raise
New York, N.Y (USA) and Paris (France), April 11, 2019 – Zionexa, a radiopharmaceutical company specialized in the development and commercialization of innovative molecular imaging companion diagnostics (CDx) for targeted therapies in oncology, announced today that it has completed a second capital raise of $5 Million via two French investment funds, IXO and SofiMac, as well as Denos, its majority shareholder.
This funding has been realized in line with Zionexa’s initial 2018 plan in order to raise a total of $10 Million with the first 12 months in order to register with the FDA (Food and Drug Administration), its first pipeline molecule, EstroTep, an innovative biomarker for targeted in-vivo diagnostic of metastatic breast cancer.
These additional funds will also enable Zionexa to further develop its pipeline of other innovative molecules, notably with the launch of multicentric Phase III clinical trials in Europe that Zionexa will
sponsor. A more significant third fundraising is planned within the next 12 months, to finance the commercial launches of EstroTep, in the U.S. and France.